GenePOC launches revogene Instrument and GenePOC GBS LB assay in Canada

GenePOC asserted the launch of GenePOC GBS LB assay which is implied to be in its home market for the revogene instrument. The revogene is an automated stand-alone instrument that enables testing from single-use proprietary microfluidic cartridges, with fluorescence-based real-time polymerase chain reaction platform to deliver an accurate diagnosis.

GBS is the leading cause of infection in infants worldwide with a fatality rate between 4-6%. The SOGC guideline recommends universal antepartum screening for women at 35-37 weeks of gestation, along with intrapartum antibiotic prophylaxis. While this has resulted in a decrease in early onset disease (EOD) rate, there is still an ongoing need for more sensitive GBS detection.

Patrice Allibert, PhD, CEO of GenePOC said “We are passionate at GenePOC about eliminating the highly debilitating effects of EOD which include meningitis, pneumonia and in some cases death. In launching the GBS LB assay, we are directly addressing that unmet clinical need and meeting the market expectations.”